ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE ...

Revenue for 2025 is projected to grow by 9% to 13%, supported by double-digit growth in tablet sales across all regions. North America tablet sales are expected to grow modestly, with particular ...

European tablet sales increased by 32%, solidifying market momentum. 2024 was a record year for Alk-Abello AS (AKBLF), with revenue up 15% and earnings improving by 65% in local currencies.